Galderma Group AG Registered Shares GDERF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Galderma Raises 2026 Sales Guidance on Strong Growth
-
Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S. — Update
-
Galderma Shares Fall After Bid to Launch Botox Rival in U.S. Hits FDA Setback
-
Galderma Application for Product to Rival Botox Turned Down Again by FDA
-
Galderma Shares Gain After Sales Increase, Confidence on Outlook
-
L'Oreal Doubles Stake in Swiss Skincare Company Galderma — Update
-
L'Oreal Doubles Stake in Swiss Skincare Company Galderma
-
Galderma Shares Rise After Guidance Lift
Trading Information
- Previous Close Price
- $219.95
- Day Range
- $215.75–228.55
- 52-Week Range
- $160.00–248.46
- Bid/Ask
- $134.49 / $319.92
- Shares Outstanding
- 233.19M
- Market Cap
- $53.61B
- Volume/Avg
- 4 / 1,084
Key Statistics
- Price/Earnings (Normalized)
- 59.07
- Price/Sales
- 9.09
- Dividend Yield (Trailing)
- 0.20%
- Dividend Yield (Forward)
- 0.20%
- Total Yield
- 0.87%
Company Profile
Galderma was formed in 1981 as a joint venture between Nestle and L’Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma’s science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Growth
- Total Number of Employees
- 7,600
- Website
- https://www.galderma.com
Competitors
Valuation
|
Metric
|
GDERF
|
BEI
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 59.07 | 13.55 | 22.81 |
Price/Book Value | 6.49 | 1.92 | — |
Price/Sales | 9.09 | 1.81 | 6.83 |
Price/Cash Flow | 45.05 | 14.77 | 18.82 |
Price/Earnings
GDERF
BEI
ABBV
Financial Strength
|
Metric
|
GDERF
|
BEI
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.93 | 1.50 | 0.49 |
Current Ratio | 1.24 | 2.00 | 0.81 |
Interest Coverage | 6.84 | 39.15 | 3.89 |
Quick Ratio
GDERF
BEI
ABBV
Profitability
|
Metric
|
GDERF
|
BEI
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 7.31% | 7.60% | 14.29% |
Return on Equity (Normalized) | 12.07% | 11.37% | — |
Return on Invested Capital (Normalized) | 10.17% | 10.83% | 32.02% |
Return on Assets
GDERF
BEI
ABBV
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|#>sBM@? | LOCK|gvBd | $72B | |||
| Haleon PLC ADR
HLN
| LOCK|yBvc^tm | LOCK|$v | $43B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|mpRX^xr | LOCK|N!wtP | $41B | |||
| Zoetis Inc Class A
ZTS
| LOCK|CCVz$vB | LOCK|nX& | $31B | |||
| Viatris Inc
VTRS
| LOCK|Q#%W<< | LOCK|<< | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|pp | LOCK|w% | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|vJ#hm$J | LOCK|xx> | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|#tzT>% | LOCK|%P | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|&kKy&m | LOCK|^@rYK | $3B | |||
| Perrigo Co PLC
PRGO
| LOCK|h^?FLw | LOCK|#% | $2B |
United States